{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Overall response rate was assessed according to Immune-related Response Criteria (irRC) (Wolchok, Hoos et al. 2009). ORR is the number of participants with a best overall response of irCR or irPR.\n\nirCR is defined as complete disappearance of all lesions with no new lesions; irPR as a ≥50% decrease in tumor burden from baseline; both are confirmed ≥4 weeks after initial documentation.\n\nOnly participants with adequate irRC tumor assessments (baseline and ≥1 post-baseline) and without major protocol deviations, were included in the analysis.","groups":[{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG000","title":"Part H: Pegilodecakin 0.8/1 mg + Pembrolizumab"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG001","title":"Part H: Pegilodecakin 1.6/2 mg + Pembrolizumab"},{"description":"Participants received 3.2 or 4 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG002","title":"Part H: Pegilodecakin 3.2/4 mg + Pembrolizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received at least one dose of study intervention(s) and had an adequate irRC tumor assessment were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From Date of First Dose of Study Drug until Disease Progression or Death (Up to 48 months)","title":"Part H: Number of Participants With Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}